|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Verzenio
|
|
gptkbp:activities
|
CDK inhibitor
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Verzenio
|
|
gptkbp:can_be_used_with
|
gptkb:letrozole
gptkb:tamoxifen
gptkb:anastrozole
|
|
gptkbp:clinical_trial
|
gptkb:MONARCH_1
gptkb:MONARCH_2
gptkb:MONARCH_3
Phase III
adjuvant therapy
monotherapy
MONARCH 0
|
|
gptkbp:contraindication
|
severe renal impairment
liver impairment
|
|
gptkbp:developed_by
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:effective_date
|
gptkb:2017
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
abemaciclib
|
|
gptkbp:indication
|
gptkb:hormone_receptor-positive_breast_cancer
metastatic breast cancer
|
|
gptkbp:ingredients
|
C22 H24 N4 O2
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_atype_of
|
L01 E E03
|
|
gptkbp:is_monitored_by
|
liver function tests
complete blood count
|
|
gptkbp:is_used_for
|
gptkb:healthcare_organization
|
|
gptkbp:lifespan
|
approximately 18 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:Japan
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:pharmacokinetics
|
highly protein-bound
inhibits cell cycle progression
|
|
gptkbp:provides_information_on
|
ASCO guidelines
ESMO guidelines
NCCN guidelines
|
|
gptkbp:research_areas
|
oncology
breast cancer treatment
|
|
gptkbp:rounds
|
hepatic
|
|
gptkbp:side_effect
|
fatigue
nausea
diarrhea
liver enzyme elevation
neutropenia
|
|
gptkbp:targets
|
CD K6
CD K4
|
|
gptkbp:type_of
|
1232024-40-5
|
|
gptkbp:weight
|
364.45 g/mol
|